Latest News

MEI Pharma Appoints Tina C. Beamon, J.D., as Chief Compliance Officer
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
MEI Pharma and Kyowa Kirin to Present Clinical Data from Ongoing Studies Evaluating Zandelisib for Lymphoma at the 16th International Conference on Malignant Lymphoma Virtual Scientific Program
MEI Pharma and Kyowa Kirin Announce First Patient with Marginal Zone Lymphoma Dosed in Expanded Global Phase 2 TIDAL Study Evaluating Zandelisib